We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Two-Stage Algorithm Evaluated for Respiratory Viral Infections

By LabMedica International staff writers
Posted on 19 Apr 2018
New on-demand multiplex molecular respiratory viral diagnostics offer superior performance although can be expensive and some platforms cannot process multiple specimens simultaneously.

The recent development of commercial panel-based molecular diagnostics for the rapid detection of pathogens in positive blood culture bottles, respiratory specimens, stool, and cerebrospinal fluid has resulted in a paradigm shift in clinical microbiology and clinical practice.

Scientists from Tufts Medical Center (Boston, MA, USA) performed a retrospective study reviewing results of patients tested for respiratory viruses following introduction of a two-stage testing algorithm incorporating an initial screen with Sofia immunoassay and then secondary Biofire FilmArray, and compared to a period when only FilmArray was used. More...
Specifically, 1,814 samples were processed with the two-stage method during the winter influenza season. The protocol was then compared to 1,162 samples processed by FilmArray alone in the summer months.

The team was able to diagnose 282 cases of influenza with the Quidel Sofia influenza immunoassay using the two-stage approach. It then tested all nasopharyngeal specimens that were shown to be negative for influenza by immunoassay with the FilmArray panel, picking up an additional 163 influenza cases that would otherwise have been missed by immunoassay alone. The two-stage approach also included a respiratory syncytial virus (RSV) immunoassay test in children under age five and in adults upon physician request, testing 363 patients. Approximately 28% of samples were Sofia RSV negative, but FilmArray RSV positive, and an additional 71 RSV cases were discovered by FilmArray in patients who did not have the immunoassay. Significantly more patients received their diagnosis within 90 minutes in winter despite testing more samples, and approximately USD 36,000 was saved.

Brad J. Gardiner, an infectious diseases clinician and co-author of the study, said, “If you make a diagnosis that changes the patient's outcome, that's money well spent, but if you are diagnosing people with rhinovirus and it makes no difference, perhaps that money could have been spent better elsewhere.” The study was published on March 12, 2018, in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:
Tufts Medical Center


Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.